Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ANNX vs PVLA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PVLA Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 3–2 Matrix Metrics)

PVLA Overall Winner 6-Pillar Tally: ANNX 1 – 3 PVLA (2 Tie) Matrix Metrics: ANNX 2 – 3 PVLA

As of Nov 17, 2026, Palvella Therapeutics, Inc. (PVLA) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ANNX carries a Unified Composite Score of 43.5/100 (HOLD) at $3.48 (N/M Forward P/E, 0.0% operating margin), whereas PVLA carries 40.8/100 (SELL) at $142.94 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ANNX currently prints a higher short-term Unified Composite Score (43.5/100 HOLD vs. PVLA 40.8/100 SELL), PVLA captures the overall institutional head-to-head verdict (3–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: ANNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3); meanwhile PVLA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ANNX vs PVLA
ANNX NASDAQ
Annexon, Inc. Common Stock
Pharmaceutical Preparations
$3.48
-2.38% 1D
Market Cap $747.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.69β · 63% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 37.0 Fund 55.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.2%), weak momentum, RSI 36
RSI-14: 36.3 · SMA20: $3.96 · SMA50: $3.98
PVLA NASDAQ Head-to-Head Winner
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$142.94
-1.15% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.68β · 75% Vol
Unified Composite Score
40.8 / 100 SELL
Tech 15.0 Fund 44.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.8%) with fading momentum, RSI 45
RSI-14: 45.5 · SMA20: $148.79 · SMA50: $143.10

6-Pillar Scorecard Institutional Category Breakdown (ANNX 1 – 3 PVLA)

Columns: Metric · ANNX · PVLA
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale PVLA
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $747.8M $2.2B
3. Profitability & Quality PVLA
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -130.8% -63.4%
4. Balance Sheet & Cash Flow PVLA
Cash Generation (TTM) -$190M -$43M
Cash Flow Margin N/A N/A
Net Cash / Leverage $29M Net Cash $193M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ANNX
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 569.3% (100th %ile) 49.8% (2nd %ile)
Put/Call OI Skew 0.09x (Call-Skewed) 5.53x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ANNX (2) vs PVLA (3)
Institutional Metric ANNX PVLA Criterion Row Edge
Market Capitalization
Scale
$747.8M $2.2B Larger Scale PVLA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-130.8% -63.4% Higher ROE PVLA
52-Week Range Position
Momentum
18% ($3–$7) 66% ($72–$180) Stronger Trend PVLA
Beta / 30D Volatility
Risk Regime
1.69β · 63% Vol 1.68β · 75% Vol Lower Realized Risk ANNX
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 40.8 / 100 (SELL) Higher Composite ANNX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$190M ($29M Net Cash) -$43M ($193M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PVLA +29.34 pp
ANNX: -13.09% · PVLA: +16.25%
3M Horizon PVLA +31.96 pp
ANNX: -36.64% · PVLA: -4.68%
6M Horizon PVLA +59.92 pp
ANNX: -29.02% · PVLA: +30.9%
1Y Horizon PVLA +42.14 pp
ANNX: +28.6% · PVLA: +70.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANNX vs PVLA. Trailing 12-month operating profitability (ANNX 0.0% vs PVLA 0.0%) and valuation multiples (ANNX N/M vs PVLA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ANNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-130.8% · N/M
PVLA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-63.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ANNX BREAKDOWN
88d in phase · OBV DISTRIBUTION
Current IV 569.3%
IV Percentile 100th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ANNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PVLA CONSOLIDATION
71d in phase · OBV DISTRIBUTION
Current IV 49.8%
IV Percentile 2nd %ile
Put/Call OI Skew 5.53x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ANNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $747.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ANNX vs PVLA Key Questions & Quantitative Answers

As of Nov 17, 2026, Palvella Therapeutics, Inc. (PVLA) is the stronger overall head-to-head candidate over Annexon, Inc. (ANNX) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ANNX carries a Unified Composite Score of 43.5/100 (HOLD) at $3.48 (N/M Forward P/E, 0.0% operating margin), whereas PVLA carries 40.8/100 (SELL) at $142.94 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ANNX currently prints a higher short-term Unified Composite Score (43.5/100 HOLD vs. PVLA 40.8/100 SELL), PVLA captures the overall institutional head-to-head verdict (3–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: ANNX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.3); meanwhile PVLA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PVLA leads the Growth & Scale pillar: ANNX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PVLA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ANNX generates N/A in USD-normalized revenue versus N/A for PVLA. In operating R&D and SG&A reinvestment, ANNX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PVLA.

ANNX and PVLA trade at balanced relative valuation multiples. ANNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANNX (-130.8% ROE) versus PVLA (-63.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ANNX carries 569.3% implied volatility (100th %ile, Extreme (>80th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.69β · 63% Vol realized risk). By comparison, PVLA carries 49.8% implied volatility (2nd %ile, Compressed (<25th %ile)), a 5.53x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.68β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.